Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma - A report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE)

European Journal of Cancer

Volumn 48, Issue 15, 2012, Pages 2409-2416

  Minard Colin, Véronique ^a   Ichante, Jean Laurent ^b   Nguyen, Laurent ^c   Paci, Angelo ^b   Orbach, Daniel ^d   Bergeron, Christophe ^e   Defachelles, Anne Sophie ^f   André, Nicolas ^g   Corradini, Nadège ^h   Schmitt, Claudine ⁱ   Tabone, Marie Dominique ^j   Blouin, Pascale ^k   Sirvent, Nicolas ^l   Goma, Gisele ^b   Geoerger, Birgit ^a,m   Oberlin, Odile ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IGR   (France)

^c Centre d'Immunologie Pierre Fabre   (France)

^d INSTITUT CURIE   (France)

^e Institut D'Hématologie et Oncologie Pédiatrique   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g TIMONE HOSPITAL   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ CHUNancy ^*  (France)

^j ARMAND TROUSSEAU HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l MONTPELLIER UNIVERSITY HOSPITAL   (France)

^m UPRES EA 3535 Pharmacology and New Treatments with Cancer   (France)

more..

Author keywords

Cyclophosphamide; Metronomic; Phase II; PK; Rhabdomyosarcoma; Vinorelbine

Indexed keywords

CYCLOPHOSPHAMIDE; NAVELBINE;

ADOLESCENT; ADULT; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HEMOPERITONEUM; HEMORRHAGIC CYSTITIS; HOSPITALIZED CHILD; HUMAN; HYPONATREMIA; INFANT; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PEDIATRIC SURGERY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; RECURRENCE; RHABDOMYOSARCOMA; SARCOMA; VINBLASTINE; YOUNG ADULT;

EID: 84866734818     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.04.012     Document Type: Article

References (40)

1. S. Binet, E. Chaineau, and A. Fellous Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules Int J Cancer 46 1990 262 266
2. A. Fellous, R. Ohayon, and T. Vacassin Biochemical effects of Navelbine on tubulin and associated proteins Semin Oncol 16 1989 9 14
3. M. Casanova, A. Ferrari, and F. Spreafico Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma Cancer 94 2002 3263 3268
4. S. Epelman, and R. Melaragno High response rate of vinorelbine in children and adolescents with refractory or recurrent RMSs Med Ped Oncol 33 1999 227 [abstr. P-147]
5. V. Biassoni, M. Casanova, and F. Spreafico A case of relapsing glioblastoma multiforme responding to vinorelbine J Neurooncol 80 2006 195 201
6. M. Johansen, J. Kuttesch, and W.A. Bleyer Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group Clin Cancer Res 12 2006 516 522
7. J.F. Kuttesch Jr., M.D. Krailo, and T. Madden Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study Pediatr Blood Cancer 53 2009 590 593
8. H.M. Maurer, M. Beltangady, and E.A. Gehan The Intergroup Rhabdomyosarcoma Study-I. A final report Cancer 61 1988 209 220
9. H.M. Maurer, E.A. Gehan, and M. Beltangady The Intergroup Rhabdomyosarcoma Study-II Cancer 71 1993 1904 1922
10. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 2004 423 436
11. G. Bocci, K.C. Nicolaou, and R.S. Kerbel Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res 62 2002 6938 6943
12. E. Pasquier, M. Kavallaris, and N. Andre Metronomic chemotherapy: new rationale for new directions Nat Rev Clin Oncol 7 2010 455 465
13. J. Taieb, N. Chaput, and N. Schartz Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines J Immunol 176 2006 2722 2729
14. T. Nakahara, H. Uchi, and A.M. Lesokhin Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs Blood 115 2010 4384 4392
15. F. Ghiringhelli, C. Menard, and P.E. Puig Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 2007 641 648
16. S. Viaud, C. Flament, and M. Zoubir Cyclophosphamide induces differentiation of Th17 cells in cancer patients Cancer Res 71 2011 661 665
17. N. Martin-Orozco, P. Muranski, and Y. Chung T helper 17 cells promote cytotoxic T cell activation in tumor immunity Immunity 31 2009 787 798
18. M. Casanova, A. Ferrari, and G. Bisogno Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol Cancer 101 2004 1664 1671
19. A.B. Miller, B. Hoogstraten, and M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
20. National Cancer Institute Investigator's hand-book: a manual for participants in clinical trials of investigational agents sponsored by DCTD, NCI 1993 Bethesda, MD National Cancer Institute
21. L. Nguyen, B. Tranchand, and C. Puozzo Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials Br J Clin Pharmacol 53 2002 459 468
22. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
23. G. Bisogno, R. Riccardi, and A. Ruggiero Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma Cancer 106 2006 703 707
24. L.M. Wagner, K.R. Crews, and L.C. Iacono Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors Clin Cancer Res 10 2004 840 848
25. T. Zwerdling, M. Krailo, and P. Monteleone Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group Cancer 106 2006 1821 1828
26. A. Wagner-Bohn, M. Paulussen, and J.P. Vieira Pinheiro Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin Anticancer Drugs 17 2006 859 864
27. B. Geoerger, J. Chisholm, and M.C. Le Deley Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study Eur J Cancer 47 2011 230 238
28. O. Beaty 3rd, O. Berg, and S. Blaney A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study Pediatr Blood Cancer 55 2010 440 445
29. G. Vassal, D. Couanet, and E. Stockdale Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group J Clin Oncol 25 2007 356 361
30. L. Mascarenhas, E.R. Lyden, and P.P. Breitfeld Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group J Clin Oncol 28 2010 4658 4663
31. C. Puozzo, H.L. Ung, and G. Zorza A high performance liquid chromatography method for vinorelbine and 4-O-deacetyl vinorelbine: a decade of routine analysis in human blood J Pharm Biomed Anal 44 2007 144 149
32. S.N. de Wildt, M. de Hoog, and A.A. Vinks Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients Crit Care Med 31 2003 1952 1958
33. J. Bouligand, T. Storme, and I. Laville Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products J Pharm Biomed Anal 38 2005 180 185
34. J.H. Beijnen, R. van Gijn, and E.E. Challa Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids J Parenter Sci Technol 46 1992 111 116
35. R. Kennedy, D. Groepper, and M. Tagen Stability of cyclophosphamide in extemporaneous oral suspensions Ann Pharmacother 44 2010 295 301
36. G.M. Brodeur, J. Pritchard, and F. Berthold Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J Clin Oncol 11 1993 1466 1477
37. EMA. Committee for proprietary medicinal products (CPMP): note for Guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98, 2001.
38. J.C. Van Heugen, J. De Graeve, and G. Zorza New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces J Chromatogr A 926 2001 11 20
39. D. Khayat, O. Rixe, and R. Brunet Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design Cancer Chemother Pharmacol 54 2004 193 205
40. M. Marty, P. Fumoleau, and A. Adenis Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors Ann Oncol 12 2001 1643 1649